ClinVar Miner

Submissions for variant NM_001370658.1(BTD):c.399G>A (p.Glu133=)

dbSNP: rs397514360
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Center for Pediatric Genomic Medicine, Children's Mercy Hospital and Clinics RCV000425369 SCV000511171 likely pathogenic not provided 2016-09-23 criteria provided, single submitter clinical testing
Invitae RCV000021928 SCV000630333 pathogenic Biotinidase deficiency 2023-12-26 criteria provided, single submitter clinical testing This sequence change affects codon 153 of the BTD mRNA. It is a 'silent' change, meaning that it does not change the encoded amino acid sequence of the BTD protein. This variant also falls at the last nucleotide of exon 3, which is part of the consensus splice site for this exon. This variant is present in population databases (rs397514360, gnomAD 0.0009%). This variant has been observed in individual(s) with biotinidase deficiency (PMID: 9396567, 10400129; Invitae). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 25009). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic.
GeneDx RCV000425369 SCV001758861 likely pathogenic not provided 2020-10-07 criteria provided, single submitter clinical testing In silico analysis, which includes splice predictors and evolutionary conservation, supports a deleterious effect; Not observed at a significant frequency in large population cohorts (Lek et al., 2016); This variant is associated with the following publications: (PMID: 10400129, 20556795, 11668630, 11865279, 9396567)
Baylor Genetics RCV000021928 SCV004211442 likely pathogenic Biotinidase deficiency 2023-07-20 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000021928 SCV004223036 likely pathogenic Biotinidase deficiency 2023-11-21 criteria provided, single submitter clinical testing Variant summary: BTD c.399G>A (p.Glu133Glu) alters the conserved, last nucleotide of exon 3 and therefore could affect mRNA splicing, leading to a significantly altered protein sequence. Several computational tools predict a significant impact on normal splicing: Four predict the variant abolishes a 5' splicing donor site. These predictions have yet to be confirmed by functional studies, although one study attempted to confirm a splicing impact but was unable to detect any aberrantly spliced transcripts or transcripts with the variant of interest in patients (e.g., Pomponio_1997). These findings suggest mRNA produced from the variant allele may be rapidly degraded. The variant allele was found at a frequency of 4e-06 in 251142 control chromosomes (gnomAD). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.399G>A has been reported in the literature in several compound heterozygous individuals affected with Biotinidase Deficiency (e.g., Pomponio_1997, Norrgard_1999, Wolf_2002). These data indicate that the variant is likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function, finding that biotinyl-hydrolase activity was <10% of normal activity in serum from patients harboring a null variant in trans (e.g., Pomponio_1997, Norrgard_1999). The following publications have been ascertained in the context of this evaluation (PMID: 10400129, 9396567, 11865279). Three submitters have reported clinical-significance assessments for this variant to ClinVar after 2014. All submitters classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as likely pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.